FDA continues review of Rezolute's congenital HI drug data

September 9, 2026 7:00 AM

Rezolute, Inc. (Nasdaq: RZLT) said the U.S. Food and Drug Administration is continuing to review data submitted from its Phase ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found